Bayer studies eye drug delivery in collaboration with Johns Hopkins

Bayer is collaborating with Johns Hopkins University's Wilmer Eye Institute to develop new forms of drug delivery to the back of the eye. Targeted diseases include age-related macular degeneration and diabetic macular edema, which both result in in vision loss. More from FierceBiotech

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.